1-Year Comparison of Clinical and Endoscopic Outcomes of Tofacitinib vs Vedolizumab for Ulcerative Colitis After Anti-Tumor Necrosis Factor Failure: A Real-World Cohort Study in the United States

被引：0
|
作者：
Dalal, Rahul S. [1 ]
Sharma, Puza P. [2 ]
Bains, Kanwal [3 ]
Pruce, Jordan C. [1 ]
Allegretti, Jessica R. [1 ,4 ]
机构：
[1] Harvard Med Sch, Brigham & Womens Hosp, Dept Med, Div Gastroenterol Hepatol & Endoscopy, Boston, MA USA
[2] Pfizer Inc, New York, NY USA
[3] Harvard Med Sch, Brigham & Womens Hosp, Dept Nutr, Boston, MA USA
[4] 50 Boylston St,Suite 201, Chestnut Hill, MA 02467 USA
来源：
INFLAMMATORY BOWEL DISEASES | 2023年 / 30卷 / 08期
关键词：
inflammatory bowel disease; small molecule; biologic; MAINTENANCE THERAPY; INDUCTION;
D O I：
10.1093/ibd/izad165
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
In this retrospective cohort study, tofacitinib was associated with higher adjusted odds of steroid-free clinical remission at 52 weeks and endoscopic remission within 52 weeks compared with vedolizumab. Adverse events were consistent with the known safety profiles of these agents.
引用
收藏
页码：1419 / 1422
页数：4
相关论文
共 40 条
  • [31] Real-world evidence comparison on the effectiveness of ustekinumab vs anti-TNF or vedolizumab in ulcerative colitis: induction phase results from the prospective, observational RUN-UC study
    Bokemeyer, B.
    Plachta-Danielzek, S.
    Howaldt, S.
    Mohl, W.
    Efken, P.
    Ehehalt, R.
    Kahl, M.
    Krause, T.
    Trentmann, L.
    Luegering, A.
    Schnoy, E.
    Jochum, C.
    Salmon, S. Fajardo
    Hartmann, P.
    Gilman, E.
    Schreiber, S.
    JOURNAL OF CROHNS & COLITIS, 2023, 17 : 872 - 872
  • [32] Treatment Persistence and Clinical Outcomes of Tumor Necrosis Factor Inhibitor Cycling or Switching to a New Mechanism of Action Therapy: Real-world Observational Study of Rheumatoid Arthritis Patients in the United States with Prior Tumor Necrosis Factor Inhibitor Therapy
    Wei, Wenhui
    Knapp, Keith
    Wang, Li
    Chen, Chieh-I
    Craig, Gary L.
    Ferguson, Karen
    Schwartzman, Sergio
    ADVANCES IN THERAPY, 2017, 34 (08) : 1936 - 1952
  • [33] Treatment Persistence and Clinical Outcomes of Tumor Necrosis Factor Inhibitor Cycling or Switching to a New Mechanism of Action Therapy: Real-world Observational Study of Rheumatoid Arthritis Patients in the United States with Prior Tumor Necrosis Factor Inhibitor Therapy
    Wenhui Wei
    Keith Knapp
    Li Wang
    Chieh-I Chen
    Gary L. Craig
    Karen Ferguson
    Sergio Schwartzman
    Advances in Therapy, 2017, 34 : 1936 - 1952
  • [34] LONG-TERM OUTCOMES OF TACROLIMUS VS. ANTI-TUMOR NECROSIS FACTOR AGENTS IN THE TREATMENT FOR ULCERATIVE COLITIS: A MULTI-INSTITUTIONAL, PROPENSITY SCORE MATCHING COMPARATIVE EFFICACY STUDY
    Yamada, Takuya
    Yoshihara, Takeo
    Amano, Takahiro
    Sakakibara, Yuko
    Osugi, Naoto
    Ishii, Shuji
    Egawa, Satoshi
    Araki, Manabu
    Arimoto, Yuki
    Nakahara, Masanori
    Murayama, Yoko
    Kobayashi, Ichizo
    Kinoshita, Kazuo
    Ogawa, Hiroyuki
    Hiyama, Satoshi
    Shibukawa, Narihiro
    Komori, Masato
    Okuda, Yorihide
    Kizu, Takashi
    Shinzaki, Shinichiro
    Iijima, Hideki
    Tsujii, Yoshiki
    Hayashi, Yoshito
    Takehara, Tetsuo
    GASTROENTEROLOGY, 2023, 164 (06) : S1217 - S1217
  • [35] BASELINE CHARACTERISTICS AND 1-YEAR OUTCOMES OF PATIENTS WITH NEOVASCULAR AGERELATED MACULAR DEGENERATION (NAMD) FROM THE REAL-WORLD LUMINOUS STUDY: GLOBAL RESULTS VS AUSTRALIAN COHORT
    Guymer, Robyn
    Macfadden, Wayne
    Lacey, Sue
    CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2016, 44 : 29 - 29
  • [36] Baseline characteristics and 1-year outcomes of patients with neovascular age-related macular degeneration from the real-world LUMINOUS™ study: global results vs Australian cohort
    Guymer, Robyn H.
    Macfadden, Wayne
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2016, 57 (12)
  • [37] Disease and economic burden increase with systemic lupus erythematosus severity 1 year before and after diagnosis: a real-world cohort study, United States, 2004-2015
    Jiang, Miao
    Near, Aimee M.
    Desta, Barnabas
    Wang, Xia
    Hammond, Edward R.
    LUPUS SCIENCE & MEDICINE, 2021, 8 (01):
  • [38] Improved Clinical Outcomes With Early Anti-Tumour Necrosis Factor Alpha Therapy in Children With Newly Diagnosed Crohn's Disease: Real-world Data from the International Prospective PIBD-SETQuality Inception Cohort Study
    Klomberg, Renz C. W.
    van der Wal, Hella C.
    Aardoom, Martine A.
    Kemos, Polychronis
    Rizopoulos, Dimitris
    Ruemmele, Frank M.
    Charrout, Mohammed
    Escher, Hankje C.
    Croft, Nicholas M.
    de Ridder, Lissy
    JOURNAL OF CROHNS & COLITIS, 2024, 18 (05): : 738 - 750
  • [39] Comorbidities, Health Care Utilization, and Cost of Care in Systematic Lupus Erythematous Increase with Disease Severity During 1 Year Before and After Diagnosis: A Real-World Cohort Study in the United States, 2004-2015
    Jiang, Miao
    Near, Aimee
    Desta, Barnabas
    Wang, Xia
    Hammond, Edward
    ARTHRITIS & RHEUMATOLOGY, 2019, 71
  • [40] Golimumab, a Human Anti-Tumor Necrosis Factor Monoclonal Antibody, Injected Subcutaneously Every 4 Weeks in Patients With Active Rheumatoid Arthritis Who Had Never Taken Methotrexate: 1-Year and 2-Year Clinical, Radiologic, and Physical Function Findings of a Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study
    Emery, Paul
    Fleischmann, Roy M.
    Doyle, Mittie K.
    Strusberg, Ingrid
    Durez, Patrick
    Nash, Peter
    Amante, Eric
    Churchill, Melvin
    Park, Won
    Pons-Estel, Bernardo
    Xu, Weichun
    Xu, Stephen
    Wu, Zhong
    Hsia, Elizabeth C.
    ARTHRITIS CARE & RESEARCH, 2013, 65 (11) : 1732 - 1742
1234